Nancy Valente Sells 4,616 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente sold 4,616 shares of the company’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the transaction, the executive vice president now directly owns 49,169 shares of the company’s stock, valued at approximately $542,334.07. This represents a 8.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Xencor Stock Performance

Shares of NASDAQ:XNCR opened at $8.80 on Friday. The business’s 50-day simple moving average is $10.85 and its 200 day simple moving average is $17.75. The company has a market cap of $626.21 million, a P/E ratio of -2.75 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The firm had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company’s revenue for the quarter was up 104.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.11) EPS. On average, sell-side analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wells Fargo & Company dropped their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Barclays cut their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research report on Thursday. Wedbush restated an “outperform” rating and set a $31.00 price target on shares of Xencor in a research note on Wednesday, April 30th. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Finally, William Blair initiated coverage on shares of Xencor in a research report on Monday, April 21st. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.50.

Hedge Funds Weigh In On Xencor

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XNCR. Sterling Capital Management LLC lifted its stake in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Xencor in the 4th quarter valued at approximately $34,000. CWM LLC boosted its stake in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 2,231 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.